Targeting haptoglobin could offer therapeutic benefits in conditions characterised by excessive haemolysis, such as sickle cell disease, haemolytic anaemias, and autoimmune haemolytic conditions (Bulters et al., 2018). This evidence concerns the gene HP and non-autoimmune hemolytic anemia.